Your browser is no longer supported. Please, upgrade your browser.
DRRX DURECT Corporation monthly Stock Chart
DURECT Corporation
Index- P/E- EPS (ttm)-0.05 Insider Own1.59% Shs Outstand201.88M Perf Week8.82%
Market Cap384.13M Forward P/E- EPS next Y-0.22 Insider Trans-8.51% Shs Float199.94M Perf Month5.11%
Income-9.20M PEG- EPS next Q-0.04 Inst Own54.90% Short Float4.62% Perf Quarter6.63%
Sales42.00M P/S9.15 EPS this Y27.00% Inst Trans-3.23% Short Ratio11.39 Perf Half Y-24.18%
Book/sh0.17 P/B10.88 EPS next Y-250.00% ROA-12.10% Target Price- Perf Year-11.48%
Cash/sh0.23 P/C7.90 EPS next 5Y15.00% ROE-34.00% 52W Range0.95 - 3.95 Perf YTD-51.32%
Dividend- P/FCF- EPS past 5Y10.20% ROI-44.30% 52W High-53.15% Beta1.75
Dividend %- Quick Ratio5.60 Sales past 5Y8.80% Gross Margin88.90% 52W Low94.70% ATR0.10
Employees89 Current Ratio6.00 Sales Q/Q-75.00% Oper. Margin-18.30% RSI (14)55.75 Volatility6.42% 6.21%
OptionableYes Debt/Eq0.00 EPS Q/Q-346.20% Profit Margin-21.80% Rel Volume1.09 Prev Close1.82
ShortableYes LT Debt/Eq0.60 EarningsNov 02 AMC Payout- Avg Volume812.00K Price1.85
Recom1.80 SMA205.10% SMA502.81% SMA200-6.13% Volume887,741 Change1.65%
Oct-30-20Initiated Chardan Capital Markets Buy $7
Oct-12-20Initiated ROTH Capital Buy
Jul-31-20Initiated Oppenheimer Outperform $7
Jan-31-20Initiated B. Riley FBR Buy $5
Nov-18-19Resumed Cantor Fitzgerald Overweight
Sep-06-19Initiated Cantor Fitzgerald Overweight $5
Mar-06-18Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-20-17Reiterated Laidlaw Buy $3 → $2
Oct-20-17Downgrade Stifel Buy → Hold $3 → $0.90
Oct-20-17Downgrade H.C. Wainwright Buy → Neutral
Jul-12-17Upgrade Stifel Hold → Buy $1.25 → $3
Feb-28-17Resumed H.C. Wainwright Buy $3
Apr-25-16Initiated Rodman & Renshaw Buy $4
May-01-15Reiterated Stifel Buy $1.50 → $2.50
May-01-15Reiterated Cantor Fitzgerald Buy $2.50 → $3
Mar-25-13Initiated Stifel Buy $3
Nov-01-12Downgrade C.K. Cooper Buy → Hold $3
Aug-17-12Initiated C.K. Cooper Buy $3
Jun-23-09Initiated Caris & Company Buy $5
Mar-26-09Initiated Wedbush Morgan Hold
Nov-13-20 09:00AM  
Nov-10-20 08:30AM  
Nov-02-20 11:31PM  
Oct-27-20 08:30AM  
Oct-26-20 04:30PM  
Oct-05-20 08:30AM  
Sep-30-20 04:53PM  
Sep-23-20 08:30AM  
Sep-22-20 08:30AM  
Sep-10-20 08:30AM  
Aug-27-20 08:30AM  
Aug-26-20 04:30PM  
Aug-05-20 03:31PM  
Aug-04-20 01:00AM  
Aug-03-20 06:35PM  
Jul-28-20 08:30AM  
Jul-07-20 07:35AM  
Jul-01-20 08:30AM  
Jun-29-20 09:00AM  
Jun-26-20 05:15PM  
Jun-11-20 02:45PM  
May-28-20 09:00AM  
May-26-20 08:30AM  
May-20-20 10:04AM  
May-12-20 03:00PM  
May-11-20 06:55PM  
May-04-20 05:00PM  
Apr-28-20 12:33PM  
Mar-24-20 04:18PM  
Mar-03-20 04:05PM  
Feb-26-20 07:30AM  
Feb-10-20 08:05AM  
Jan-31-20 11:14AM  
Jan-17-20 08:19AM  
Jan-16-20 02:38PM  
Jan-02-20 05:28PM  
Dec-30-19 09:24AM  
Dec-29-19 09:40PM  
Dec-19-19 05:02PM  
Dec-05-19 03:21PM  
Nov-15-19 08:00AM  
Nov-12-19 08:45AM  
Nov-06-19 05:47PM  
Nov-04-19 04:05PM  
Oct-30-19 08:00AM  
Oct-21-19 10:12AM  
Oct-18-19 10:23AM  
Oct-17-19 04:05PM  
Oct-07-19 08:00AM  
Oct-02-19 08:00AM  
Sep-26-19 08:00AM  
Sep-18-19 07:39AM  
Sep-17-19 08:00AM  
Sep-09-19 09:29AM  
Sep-07-19 12:19PM  
Sep-06-19 12:24PM  
Sep-04-19 08:00AM  
Aug-29-19 04:44PM  
Aug-20-19 10:00AM  
Aug-01-19 04:05PM  
Jul-29-19 10:08AM  
Jul-25-19 04:30PM  
Jul-22-19 08:00AM  
Jul-17-19 08:00AM  
Jun-28-19 09:15AM  
Jun-27-19 08:30AM  
Jun-26-19 07:19AM  
Jun-25-19 04:30PM  
Jun-20-19 08:00AM  
Jun-18-19 08:00AM  
Jun-11-19 10:45AM  
May-24-19 07:16PM  
May-17-19 10:50AM  
May-16-19 04:15PM  
May-08-19 11:40AM  
May-07-19 09:03PM  
May-03-19 01:26PM  
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; Gilead Sciences, Inc; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bleichroeder LP10% OwnerSep 01Sale1.68250,000420,00026,414,656Sep 02 04:25 PM
Joice Judy RSr. VP Operations & Corp QAJun 03Option Exercise0.7857,82045,10067,611Jun 05 08:33 PM
Joice Judy RSr. VP Operations & Corp QAJun 03Sale2.4557,820141,76332,747Jun 05 08:33 PM
Bleichroeder LP10% OwnerMay 26Sale2.5039,38898,52526,664,656May 28 06:29 PM
Bleichroeder LP10% OwnerFeb 06Buy1.6575,000123,62326,704,044Feb 06 06:10 PM
Bleichroeder LP10% OwnerFeb 05Buy1.6974,998126,77726,629,044Feb 06 06:10 PM
Bleichroeder LP10% OwnerFeb 04Buy1.7077,500131,51026,554,046Feb 06 06:10 PM